SynthesisFrontiers in nutrition2024
Prevalence of, and factors associated with, sarcopenia in Iran: a systematic review and meta-analysis.
Synthesis in Frontiers in nutrition, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Insulin resistance and sarcopenia: independent and combined associations with obesity and dietary protein intake.Journal of endocrinological investigation · 2026Article
- Sarcopenia and its association with physical activity and sedentary time in older adults on the Bushehr Elderly Health program.Scientific reports · 2026Article
- Association between the digestion-resistant bioactive peptide content in dairy products and the risk of sarcopenia in Iranian elderly: a case-control study.Journal of health, population, and nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Several studies have assessed the epidemiology of sarcopenia in Iran with conflicting results, but comprehensive information has remained limited. Therefore, we aimed to perform a systematic review and meta-analysis of the prevalence of sarcopenia and its associated factors among Iranian population. Methods: We searched in Embase, PubMed, Scopus, and Google Scholar, as well as Persian databases including the Scientific Information Database and Magiran, from inception to 31 May 2024. We included cross-sectional observational studies reporting the prevalence rate of, and/or factors associated with, sarcopenia in Iranian population. The pooled prevalence of sarcopenia was estimated using a random-effects model. Results: Totally, 14 eligible studies were included. The overall pooled prevalence of sarcopenia in Iran was 22.1% (95% confidence interval [CI]: 18.7-25.6). This rate in older adult population (≥60 years) was 23.5% (95% CI: 17.9-29.0). Sarcopenia was more prevalent in men (23.2% [95% CI: 21.3-25.1]) than in women (15.5% [95% CI: 9.2-21.9]). The prevalence of severe sarcopenia was 24.5% (95% CI: 16.9-32.0). Factors associated with an increased risk of sarcopenia included older age, male gender, higher body fat, lower socioeconomic status, lower education, insufficient physical activity, diabetes, smoking, and malnutrition; conversely, dietary patterns rich in anti-inflammatory nutrients, Mediterranean diet adherence, and higher mineral and vitamin intake were associated with a lower likelihood of sarcopenia. Conclusion: The prevalence of sarcopenia is notably high in Iran, particularly among men and older ages. These findings emphasize the need for targeted interventions in nutrition and lifestyle to reduce sarcopenia risk and improve quality of life among Iranians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.